secwatch.observer — SEC 8-K summary
======================================

Issuer:     JUPITER NEUROSCIENCES, INC. (JUNS)
CIK:        0001679628
Form:       8-K
Filed at:   2026-07-21T20:05:31+00:00
Accession:  0001493152-26-034077
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jupiter Neurosciences signs exclusive US license for PharmAla's ALA-002 MDMA program
--------------------------------------------------------------------------------

- Upfront payment of $3.33M: $1.5M cash (net of $600K escrow) plus $1.83M in Jupiter common stock.
- Development milestones up to $23.33M: $3.33M on Phase 3 first dosing, $20M on first FDA NDA approval.
- Commercialization milestones up to $73.33M: $10M at $333M net sales, $30M at $1B, $33.33M at $2B.
- Royalty of 3% on net sales in the Territory, beginning after the third commercialization milestone is payable.
- Exclusive license for all human therapeutic uses in the US; Jupiter must use commercially reasonable efforts to develop and commercialize.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/0001493152-26-034077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer